- Home
- BRKL vs NEO Comparison
BRKL vs NEO Comparison
Compare BRKL & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRKL
- NEO
- Stock Information
- Founded
- BRKL 1871
- NEO 2001
- Country
- BRKL United States
- NEO United States
- Employees
- BRKL N/A
- NEO N/A
- Industry
- BRKL Savings Institutions
- NEO Precision Instruments
- Sector
- BRKL Finance
- NEO Health Care
- Exchange
- BRKL Nasdaq
- NEO Nasdaq
- Market Cap
- BRKL 948.1M
- NEO 1.0B
- IPO Year
- BRKL 1998
- NEO 1999
- Fundamental
- Price
- BRKL $10.95
- NEO $8.17
- Analyst Decision
- BRKL Buy
- NEO Buy
- Analyst Count
- BRKL 2
- NEO 9
- Target Price
- BRKL $15.25
- NEO $12.63
- AVG Volume (30 Days)
- BRKL 884.6K
- NEO 2.7M
- Earning Date
- BRKL 10-22-2025
- NEO 11-04-2025
- Dividend Yield
- BRKL 4.93%
- NEO N/A
- EPS Growth
- BRKL 2.47
- NEO N/A
- EPS
- BRKL 0.88
- NEO N/A
- Revenue
- BRKL $345,393,000.00
- NEO $689,189,000.00
- Revenue This Year
- BRKL $53.95
- NEO $10.40
- Revenue Next Year
- BRKL $68.33
- NEO $10.11
- P/E Ratio
- BRKL $12.44
- NEO N/A
- Revenue Growth
- BRKL 2.90
- NEO 9.70
- 52 Week Low
- BRKL $9.28
- NEO $4.72
- 52 Week High
- BRKL $13.15
- NEO $19.12
- Technical
- Relative Strength Index (RSI)
- BRKL 51.60
- NEO 62.20
- Support Level
- BRKL $26.22
- NEO $7.36
- Resistance Level
- BRKL $26.95
- NEO $8.42
- Average True Range (ATR)
- BRKL 0.69
- NEO 0.44
- MACD
- BRKL -0.01
- NEO 0.05
- Stochastic Oscillator
- BRKL 32.55
- NEO 67.91
About BRKL Brookline Bancorp Inc.
Brookline Bancorp Inc operates as a multi-bank holding company. It offers commercial, business, and retail banking services, including a full complement of cash management products, online banking services, and consumer and residential loans.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.